Text Size: a  |   a 

Coherus' Oral Therapy for Relapsing MS Seen to Reduce Brain Lesions by Half

July 1st, 2016

A reduction in the development rate of new brain lesions by nearly 50 percent previously untreated relapsing-remitting multiple sclerosis patients was recently reported. This is a result of Coherus BioSciences’  candidate therapy for MS, CHS-131.

CHS-131 has anti-inflammatory effects in the brain without being immunosuppressive, which is contrasting to most other MS drugs. Coherus believes that because of this, CHS-131 might become a first-line treatment either alone or combined with other MS drugs. The Phase 2b trial randomized patients to receive either CHS-131 or a placebo in a double-blind manner. It also showed that the treatment didn’t give a new rise to many of the side effects linked to other MS oral drugs.

227 patients with RRMS were included in this study which compared two doses of the drug, 1mg and 3mg, given orally once a day for six months. The participants were assessed through MRI at the start of the study and then again after 24 weeks of treatment. The results showed that patients in the higher dose group had 46.3 percent fewer brain lesions in comparison to the control group that were given the placebo.

The safety and tolerability of the treatment was evaluated and side effects were reported equally among both the placebo and CHS-131 treated patients and Coherus had reported no specific safety issues.

Patricia G. Coyle, MD, vice chair at SUNY Stony Brook Neuroscience Institute said in a press release that, “These are exciting results for a new drug with non-immunosuppressive activity that is well-tolerated by patients.” Dr. Coyle, also a well-known MS expert, said that this does warrant further clinical investigation.